Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia01:30

Dementia

523
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
523
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals.

Translational psychiatry·2026
Same author

Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program.

Diabetes·2026
Same author

Biopsychosocial risk factors for Alzheimer's disease and related dementias in UK immigrants from the Middle East and North Africa (MENA).

medRxiv : the preprint server for health sciences·2026
Same author

Brain age prediction in generalized anxiety disorder using a convolutional neural network.

Translational psychiatry·2026
Same author

Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.

Nature communications·2026
Same author

Alzheimer's disease-like brain pattern biomarker: capturing risks and predicting disease onset.

Molecular psychiatry·2026
Same journal

Somatosensory cortex shapes perceptual decision bias via the superior colliculus.

Research square·2026
Same journal

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Research square·2026
Same journal

Supporting Implementation of the National Standards for Cancer Survivorship Care: Development of the Cancer Survivorship Maturity Model (CSMM).

Research square·2026
Same journal

Operationalizing a walking exercise prescription based on 6-minute walk test results.

Research square·2026
Same journal

Age but not sex modifies lymphoid immune responses in murine sepsis.

Research square·2026
Same journal

Indirect effect, through aspects of neighborhood affluence and racial/ethnic composition, of receiving a Section 8 voucher on the prevalence of psychiatric disorders among boys and girls in the Moving to Opportunity study.

Research square·2026
See all related articles

Related Experiment Video

Updated: Jan 16, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.1K

Alzheimer's Disease-Like Brain Pattern Biomarker: Capturing Risks and Predicting Disease Onset.

Peter Kochunov1, Si Gao1, Lauren Salminen2

  • 1The University of Texas Health Science Center at Houston.

Research Square
|September 26, 2025
PubMed
Summary
This summary is machine-generated.

A new Regional Vulnerability Index (RVI-AD) measures brain similarity to Alzheimer's disease (AD) patterns. This biomarker detects early AD risks from genetic and cardiovascular factors, predicting dementia conversion in at-risk individuals.

Keywords:
Alzheimer’s diseaseBig dataRVIamyloidcerebrovascular diseaseneuroimaging

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

812
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.1K

Related Experiment Videos

Last Updated: Jan 16, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.1K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

812
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.1K

Area of Science:

  • Neuroscience
  • Biomarkers
  • Neuroimaging

Background:

  • Early detection of Alzheimer's disease (AD) is crucial for timely intervention.
  • Existing biomarkers often lack sensitivity to subtle, early pathological changes.
  • Identifying individuals at high risk for AD progression is a significant clinical challenge.

Purpose of the Study:

  • To develop and validate a novel biomarker, the Regional Vulnerability Index (RVI-AD), for early Alzheimer's disease detection.
  • To assess the association of RVI-AD with known AD risk factors, including APOE-e4 genotype and cardiovascular health.
  • To evaluate the predictive power of RVI-AD for cognitive decline and conversion to dementia.

Main Methods:

  • Calculated regional effect sizes to define AD brain deficit patterns in amyloid-positive cases versus controls.
  • Developed RVI-AD as a linear index of individual brain similarity to these AD patterns.
  • Validated RVI-AD in three cohorts: Amish Connectome Project (N=335), UK Biobank (N=26,010), and ADNI (N=1,932), assessing genetic (APOE-e4) and cardiovascular (FCVRS) risks.

Main Results:

  • RVI-AD was significantly elevated in individuals with the APOE-e4 allele across all cohorts (p<0.05).
  • Framingham Cardiovascular Risk Scores (FCVRS) contributed to higher RVI-AD in an APOE-e4-specific manner (p<0.01).
  • In the ADNI cohort, RVI-AD predicted conversion from mild cognitive impairment (MCI) to dementia within 10 years (AUC=74%), particularly within the first 3 years.

Conclusions:

  • RVI-AD effectively detects the impact of APOE-e4 and cardiovascular risks in healthy aging individuals.
  • Elevated RVI-AD predicts future dementia conversion, especially in high-risk populations.
  • RVI-AD shows promise as a noninvasive, clinically accessible biomarker for early Alzheimer's disease risk assessment.